tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Dawnrays Pharmaceutical Reports Strong Profit Growth Despite Revenue Decline in 2024

Story Highlights
Dawnrays Pharmaceutical Reports Strong Profit Growth Despite Revenue Decline in 2024

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Dawnrays Pharmaceutical Holdings Ltd. ( (HK:2348) ) has issued an update.

Dawnrays Pharmaceutical Holdings Ltd. announced its annual results for the year ending December 31, 2024, revealing a 7.9% decrease in revenue compared to 2023. Despite the revenue drop, the company reported a significant increase in profit before tax by 53.8% and profit for the year by 74.4%, attributed to higher other income and gains. The net profit margin improved by 25.1 percentage points, indicating strong financial performance despite challenges in revenue.

More about Dawnrays Pharmaceutical Holdings Ltd.

Dawnrays Pharmaceutical Holdings Ltd. is a company incorporated in the Cayman Islands, primarily engaged in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products, catering to various healthcare needs.

YTD Price Performance: 3.28%

Average Trading Volume: 171,535

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$1.89B

Find detailed analytics on 2348 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1